James Huang, Director at Connect Biopharma Holdings Ltd (CNTB), bought 1,160,000 shares at $3.45 ($4.0M) on 2026-03-31, disclosed to the SEC on 2026-04-01.
Director James Huang purchased 1.16 million shares at $3.45 on March 31, 2026, marking the largest insider buy in the company's history. This significant capital commitment comes as the stock trades near its 52-week low, potentially signaling confidence in the upcoming SEABREEZE data readout.
The stock has sold off sharply, dropping 19.05% over the past five days to trade at $2.72, which is 28.8% below its 52-week high of $3.82 but only 6.67% above its 52-week low of $2.55.
Key catalysts include the SEABREEZE study data readout expected in mid-2026 (May 22, 2026) and the largest insider purchase in the company's history on March 31, 2026, which signals strong insider conviction.
The stock faces headwinds from a negative industry buying flow of -3.31% over the last 90 days and a short interest of 2.99% on the float, which could exacerbate volatility if the SEABREEZE data disappoints.
Nothing distinguishes this filing.
| Filing → |
| ATRA | BUY | 2025-07-21 | $373K | — | Filing → |
| CASI | BUY | 2022-09-08 | $304K | — | Filing → |
| CASI | BUY | 2022-09-02 | $233K | — | Filing → |